Critical Care Medicine, The Keenan Research Centre for Biomedical Science of Saint Michael's Hospital, Toronto, Ontario, Canada.
Institute of Medical Sciences and Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Thorax. 2020 Jul;75(7):556-567. doi: 10.1136/thoraxjnl-2019-213561. Epub 2020 Jun 16.
Mesenchymal stromal cell (MSC) therapy mitigates lung injury and improves survival in murine models of sepsis. Precise mechanisms of therapeutic benefit remain poorly understood.
To identify host-derived regulatory elements that may contribute to the therapeutic effects of MSCs, we profiled the microRNAome (miRNAome) and transcriptome of lungs from mice randomised to experimental polymicrobial sepsis-induced lung injury treated with either placebo or MSCs.
A total of 11 997 genes and 357 microRNAs (miRNAs) expressed in lungs were used to generate a statistical estimate of association between miRNAs and their putative mRNA targets; 1395 miRNA:mRNA significant association pairs were found to be differentially expressed (false discovery rate ≤0.05). MSC administration resulted in the downregulation of miR-27a-5p and upregulation of its putative target gene VAV3 (adjusted p=1.272E-161) in septic lungs. In human pulmonary microvascular endothelial cells, miR-27a-5p expression levels were increased while VAV3 was decreased following lipopolysaccharide (LPS) or tumour necrosis factor (TNF) stimulation. Transfection of miR-27a-5p mimic or inhibitor resulted in increased or decreased VAV3 message, respectively. Luciferase reporter assay demonstrated specific binding of miR-27a-5p to the 3'UTR of VAV3. miR27a-5p inhibition mitigated TNF-induced (1) delayed wound closure, increased (2) adhesion and (3) transendothelial migration but did not alter permeability. In vivo, cell infiltration was attenuated by intratracheal coinstillation of the miR-27a-5p inhibitor, but this did not protect against endotoxin-induced oedema formation.
Our data support involvement of miR-27a-5p and VAV3 in cellular adhesion and infiltration during acute lung injury and a potential role for miR-27a-based therapeutics for acute respiratory distress syndrome.
间充质基质细胞(MSC)疗法减轻了脓毒症小鼠模型中的肺损伤并提高了存活率。但治疗益处的确切机制仍知之甚少。
为了确定可能有助于 MSC 治疗效果的宿主来源的调节因子,我们对随机分配到实验性多微生物脓毒症诱导的肺损伤并接受安慰剂或 MSC 治疗的小鼠的肺部 microRNA 组(miRNAome)和转录组进行了分析。
总共分析了 11997 个基因和 357 个 microRNAs(miRNAs)在肺部的表达,以生成 miRNA 与其假定的 mRNA 靶标之间关联的统计估计值;发现 1395 个 miRNA:mRNA 显著关联对的表达存在差异(错误发现率≤0.05)。MSC 给药导致脓毒症肺部中 miR-27a-5p 的下调和其假定靶基因 VAV3 的上调(调整后的 p=1.272E-161)。在人肺微血管内皮细胞中,miR-27a-5p 的表达水平在脂多糖(LPS)或肿瘤坏死因子(TNF)刺激后增加,而 VAV3 则减少。miR-27a-5p 模拟物或抑制剂的转染分别导致 VAV3 消息的增加或减少。荧光素酶报告基因测定表明 miR-27a-5p 特异性结合到 VAV3 的 3'UTR。miR27a-5p 抑制减轻了 TNF 诱导的(1)延迟伤口闭合,增加(2)粘附和(3)跨内皮迁移,但不改变通透性。在体内,通过气管内共灌输 miR-27a-5p 抑制剂可减轻细胞浸润,但这并不能防止内毒素引起的水肿形成。
我们的数据支持 miR-27a-5p 和 VAV3 参与急性肺损伤期间的细胞粘附和浸润,并且 miR-27a 为治疗急性呼吸窘迫综合征提供了一种潜在的治疗方法。